DRAK2 peptide

Cannot supply to this region.

SKU:: GTX28454
Additional Names:: Serine/Threonine Kinase 17B , Drak2 , Stk17B
Application:: Neutralisation
Concentration:: 0.20 mg/ml
Physical State:: Liquid
Storage Conditions:: -20[o]C Avoid freeze/thaw cycles.
Supplier:: Genetex
Buffer:: PBS, 0.1% BSA, 0.02% Sodium azide.
Immunogen:: serine/threonine kinase 17b
Species:: Human
Synonyms:: DAP kinase-related apoptosis-inducing protein kinase 2;death-associated protein kinase-related 2;DRAK2;serine/threonine-protein kinase 17B
Extra Details:: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.